Latest Health News

Yowie Group Ltd has responded to ASX queries detailing a significant revenue impact from reduced store facings and clarified complex loan arrangements with Keybridge Capital Limited amid ongoing solvency concerns.

Ecofibre Limited’s shares have been suspended from trading following the appointment of voluntary administrators, reflecting severe financial distress and regulatory concerns.

Forbidden Foods Limited has reported a remarkable 218% increase in April invoiced sales, driven by robust ecommerce growth and the recent integration of Oat Milk Goodness. The company is on track to surpass $4 million in annual sales, signaling strong momentum in the health and wellness FMCG sector.

Anagenics Limited has reported a net profit before tax of $138,000 for the quarter ended March 31, 2025, marking a significant turnaround following recent restructuring efforts. Despite a temporary revenue setback due to a warehousing transition, the company’s operating cash flow improved markedly.

Cazaly Resources has issued a replacement Appendix 5B for the March 2025 quarter to correct an administrative error, reaffirming a solid cash position with over six quarters of funding available.

Nuchev Limited has entered an exclusive sales agency agreement with Brauer Natural Medicines and H&S Brand Corporation, expanding its footprint in Australia's natural and complementary medicines sector. The deal covers key brands including Brauer, Skin Physics, and Rapid Loss, with potential for broader ANZ distribution.

WOTSO reports an 8% year-over-year revenue increase in Q3 FY25, driven by rising occupancy and expanding desk capacity. The company plans six new flexspace locations across Australia and New Zealand, balancing owned and leased properties.

BlinkLab Limited has raised A$7.66 million through a well-supported placement to accelerate FDA regulatory trials for its autism and ADHD diagnostic platforms, leveraging its innovative smartphone-based technology.

Eureka Group Holdings has upsized its debt facilities to $185 million with improved terms, enhancing its financial flexibility to expand residential developments across Australia.

Anatara Lifesciences has obtained a $400,000 loan advance from a major shareholder group against its estimated R&D tax refund for the first half of FY2025, providing crucial funding to support ongoing clinical trials and product development without immediate capital raising.

Memphasys Limited has completed a pivotal Phase III trial confirming its Felix™ System as best-in-class for sperm separation, while advancing regulatory and commercial efforts in China and Brazil supported by fresh capital.

EMU NL’s latest quarterly report reveals promising copper exploration parallels with Canada’s largest open-pit mine, a renewed gold project strategy, and significant corporate restructuring amid shareholder disputes.